Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alternative statistical parameter for high-throughput screening assay quality assessment.

Yunxia Sui1, Zhijin Wu

  • 1Department of Community Health, Brown University, Providence, RI 02903, USA.

Journal of Biomolecular Screening
|January 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SliceMap: a binary classification-driven 2D pipeline for detecting discriminative candidate regions in brain MRI.

Frontiers in neuroimaging·2026
Same author

RNA transcripts in salivary extracellular vesicle cargo isolated from aged populations.

Frontiers in aging·2026
Same author

TORC: Target-Oriented Reference Construction for supervised cell-type identification in scRNA-seq.

Genome biology·2025
Same author

Overexpression of the WWE domain of RNF146 modulates poly-(ADP)-ribose dynamics at sites of DNA damage.

DNA repair·2025
Same author

Downregulation of spermatogenesis-associated transcripts in the spermatozoa of idiopathic infertile men.

Andrology·2025
Same author

Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease.

EMBO molecular medicine·2025
Same journal

Functional Comparison of Neuronal Cells Differentiated from Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells under Different Oxygen and Medium Conditions.

Journal of biomolecular screening·2017
Same journal

Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.

Journal of biomolecular screening·2017
Same journal

Erratum.

Journal of biomolecular screening·2017
Same journal

Software, Database, and Information Services.

Journal of biomolecular screening·2017
Same journal

High-Throughput Platform for Identifying Molecular Factors Involved in Phenotypic Stabilization of Primary Human Hepatocytes In Vitro.

Journal of biomolecular screening·2016
Same journal

SLAS Europe High-Content Screening Conference in Dresden: A Glimpse of the Future?

Journal of biomolecular screening·2016
See all related articles

Assay quality in drug discovery is crucial. This study shows that analyzing statistical power, rather than just the Z factor, better predicts the success of identifying active compounds in high-throughput screening.

Area of Science:

  • Drug discovery
  • Biotechnology
  • Assay development

Background:

  • High-throughput screening (HTS) is vital for identifying drug candidates.
  • Assay quality is paramount for reliable HTS results.
  • The Z factor is a common metric for assay quality but may not reflect modern data analysis capabilities.

Purpose of the Study:

  • To evaluate the Z factor's effectiveness in assessing assay quality for drug discovery.
  • To explore the relationship between assay quality metrics and the power to detect true active compounds.
  • To propose improved methods for assay quality assessment in HTS.

Main Methods:

  • Analysis of Z factor implications under various conditions.
  • Linking Z factor values to the statistical power of identifying active compounds.

Related Experiment Videos

  • Investigating the impact of different error distributions on Z factor interpretation.

    • Main Results:

    • The Z factor's interpretation varies with error distributions.
    • Direct analysis of statistical power offers a more accurate measure of assay quality.
    • Current assay quality assessment may not align with advanced data analysis techniques.

    Conclusions:

    • Relying solely on the Z factor can be insufficient for robust assay quality assessment in HTS.
    • Statistical power analysis provides a more direct and reliable measure of an assay's ability to identify true hits.
    • Adjustments in data analysis should be considered when estimating assay quality parameters for optimized drug discovery efforts.